JPH0796557B2 - 新規ペプチド、その製法およびそれを含有する医薬組成物 - Google Patents
新規ペプチド、その製法およびそれを含有する医薬組成物Info
- Publication number
- JPH0796557B2 JPH0796557B2 JP62292187A JP29218787A JPH0796557B2 JP H0796557 B2 JPH0796557 B2 JP H0796557B2 JP 62292187 A JP62292187 A JP 62292187A JP 29218787 A JP29218787 A JP 29218787A JP H0796557 B2 JPH0796557 B2 JP H0796557B2
- Authority
- JP
- Japan
- Prior art keywords
- lys
- peptide
- glu
- arg
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title description 12
- 239000008194 pharmaceutical composition Substances 0.000 title description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 229960004397 cyclophosphamide Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 5
- 229960002170 azathioprine Drugs 0.000 description 5
- 230000001085 cytostatic effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 3
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 3
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000000898 Thymopoietin Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
- 208000036566 Erythroleukaemia Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102400000160 Thymopentin Human genes 0.000 description 2
- 101800001703 Thymopentin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000021841 acute erythroid leukemia Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 2
- 229960004517 thymopentin Drugs 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- FYLUBIRVRMDTFQ-HNNXBMFYSA-N (2,3,4,5,6-pentafluorophenyl) (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)OC=1C(=C(F)C(F)=C(F)C=1F)F)CCCNC(=O)OCC1=CC=CC=C1 FYLUBIRVRMDTFQ-HNNXBMFYSA-N 0.000 description 1
- COIXXKVZEXZCLU-YXWQFLTLSA-N (2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N COIXXKVZEXZCLU-YXWQFLTLSA-N 0.000 description 1
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- CVQUVFAGYIPOEK-UHFFFAOYSA-N 3h-1,3-oxazol-2-one;propan-2-one Chemical compound CC(C)=O.O=C1NC=CO1 CVQUVFAGYIPOEK-UHFFFAOYSA-N 0.000 description 1
- AKMMLVXPZWOEQH-UHFFFAOYSA-N 4-(ethoxymethyl)-2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound CCOCC1COC(C=2C=CC=CC=2)=N1 AKMMLVXPZWOEQH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010003201 RGH 0205 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000002912 lymphogenic effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical group C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- XUZLXCQFXTZASF-UHFFFAOYSA-N nitro(phenyl)methanol Chemical compound [O-][N+](=O)C(O)C1=CC=CC=C1 XUZLXCQFXTZASF-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- -1 pentafluorophenyl ester Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940034252 thymus extracts Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0825—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Glp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU864827A HUT46044A (en) | 1986-11-21 | 1986-11-21 | Process for producing immunstimulant peptides inhibiting multiplication of leukaemic cells and pharmaceutics comprising same |
| HU2251-4827/86 | 1986-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63198698A JPS63198698A (ja) | 1988-08-17 |
| JPH0796557B2 true JPH0796557B2 (ja) | 1995-10-18 |
Family
ID=10968962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62292187A Expired - Lifetime JPH0796557B2 (ja) | 1986-11-21 | 1987-11-20 | 新規ペプチド、その製法およびそれを含有する医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5041535A (en, 2012) |
| EP (1) | EP0269389B1 (en, 2012) |
| JP (1) | JPH0796557B2 (en, 2012) |
| AT (1) | ATE81134T1 (en, 2012) |
| AU (1) | AU597749B2 (en, 2012) |
| CA (1) | CA1318456C (en, 2012) |
| DE (1) | DE3782006T2 (en, 2012) |
| DK (1) | DK610287A (en, 2012) |
| ES (1) | ES2055708T3 (en, 2012) |
| GR (1) | GR3006357T3 (en, 2012) |
| HU (1) | HUT46044A (en, 2012) |
| IL (1) | IL84551A (en, 2012) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1216908B (it) * | 1987-03-19 | 1990-03-14 | Eniricerche Spa | Analoghi retro-inversi della timopentina e dei suoi frammenti, il metodo per la loro sintesi ed il loro impiego per la preparazionedi composizioni farmaceutiche. |
| DE69124274T2 (de) * | 1990-02-27 | 1997-08-14 | Agency Ind Science Techn | Oligopeptide, sie enthaltende pharmazeutische und Futterzusammensetzung und Benützung von Oligopeptiden |
| US6066622A (en) * | 1991-10-28 | 2000-05-23 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| WO1995003067A1 (en) * | 1993-07-21 | 1995-02-02 | Khavinson Vladimir Khatskelevi | Pharmaceutical with immunomodulating activity |
| CA2665351A1 (en) * | 2006-10-04 | 2008-04-10 | Inimex Pharmaceuticals Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
| RU2656188C1 (ru) * | 2017-05-03 | 2018-06-04 | Общество с ограниченной ответственностью "Анкрим" (ООО "Анкрим") | Синтетическое анальгетическое средство пептидной природы и способ его применения |
| CN118638025A (zh) | 2017-08-21 | 2024-09-13 | 细胞基因公司 | 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺 |
| HUP2300355A1 (hu) * | 2023-10-19 | 2025-04-28 | Denes Laszlo Dr | TP3 (thymopentin-analog) tartalmú gyógyszerkészítmény alkalmazása emlõs élõlények immunrendszerének védekezési mechanizmusában résztvevõ sejtaktivitásoknak és számának növelésével, a betegségek megelõzésére és/vagy kezelésére az átlagéletkor meghosszabbítására |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3821188A (en) * | 1972-06-14 | 1974-06-28 | American Home Prod | Proline and pyroglutamic acid containing tripeptides |
| GR73585B (en, 2012) * | 1978-09-11 | 1984-03-26 | Univ Miami | |
| DE3161915D1 (en) * | 1980-03-05 | 1984-02-23 | Univ Miami | Angiotensin converting enzyme inhibitors |
| HU185263B (en) * | 1981-06-12 | 1984-12-28 | Richter Gedeon Vegyeszet | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| US4629723A (en) * | 1984-06-27 | 1986-12-16 | Ortho Pharmaceutical Corporation | Potent thymopentin analogs |
| IT1188645B (it) * | 1986-04-09 | 1988-01-20 | Ellem Ind Farmaceutica | Tripeptide ad attivita' immunostimolante |
-
1986
- 1986-11-21 HU HU864827A patent/HUT46044A/hu unknown
-
1987
- 1987-11-17 CA CA000551991A patent/CA1318456C/en not_active Expired - Fee Related
- 1987-11-20 AU AU81446/87A patent/AU597749B2/en not_active Ceased
- 1987-11-20 DE DE8787310284T patent/DE3782006T2/de not_active Expired - Fee Related
- 1987-11-20 IL IL84551A patent/IL84551A/xx not_active IP Right Cessation
- 1987-11-20 AT AT87310284T patent/ATE81134T1/de not_active IP Right Cessation
- 1987-11-20 ES ES87310284T patent/ES2055708T3/es not_active Expired - Lifetime
- 1987-11-20 JP JP62292187A patent/JPH0796557B2/ja not_active Expired - Lifetime
- 1987-11-20 DK DK610287A patent/DK610287A/da unknown
- 1987-11-20 EP EP87310284A patent/EP0269389B1/en not_active Expired - Lifetime
- 1987-11-20 US US07/123,124 patent/US5041535A/en not_active Expired - Fee Related
-
1992
- 1992-11-26 GR GR920402715T patent/GR3006357T3/el unknown
Non-Patent Citations (1)
| Title |
|---|
| Ｂｉｏｐｏｌｙｍｅｒｓ，９〔１２〕（１９７０）Ｐ．１４１９〜１４２７ |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2055708T3 (es) | 1994-09-01 |
| IL84551A0 (en) | 1988-04-29 |
| ATE81134T1 (de) | 1992-10-15 |
| AU8144687A (en) | 1988-05-26 |
| US5041535A (en) | 1991-08-20 |
| DK610287A (da) | 1988-05-22 |
| AU597749B2 (en) | 1990-06-07 |
| DE3782006T2 (de) | 1993-04-22 |
| GR3006357T3 (en, 2012) | 1993-06-21 |
| HUT46044A (en) | 1988-09-28 |
| CA1318456C (en) | 1993-05-25 |
| DK610287D0 (da) | 1987-11-20 |
| EP0269389A2 (en) | 1988-06-01 |
| IL84551A (en) | 1992-06-21 |
| DE3782006D1 (en) | 1992-11-05 |
| EP0269389A3 (en) | 1990-02-07 |
| JPS63198698A (ja) | 1988-08-17 |
| EP0269389B1 (en) | 1992-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU648517B2 (en) | Methods and compositions for healing ulcers | |
| JPS5849350A (ja) | 免疫調節に影響を与えるペプチド | |
| JPH03504013A (ja) | Ｔ細胞ヘルパー活性を有するペプチド | |
| CZ287816B6 (en) | Peptide, process of its preparation, pharmaceutical preparation in which it is comprised and use thereof | |
| EP0225020A2 (en) | Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of ViP | |
| EP1309613B1 (en) | Pharmaceutical composition comprising an analgesic peptide | |
| AU620406B2 (en) | Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same | |
| JPH0796557B2 (ja) | 新規ペプチド、その製法およびそれを含有する医薬組成物 | |
| JPH0288595A (ja) | 免疫刺激性ペプチド、その製法、及び該ペプチドを含有する薬剤組成物 | |
| EP0288278B1 (en) | Chemical derivatives of GHL-CU | |
| JPS60243098A (ja) | ホモフエ８を含有するレニン阻害剤 | |
| US6057295A (en) | Oligopeptides derived from C-reactive protein fragments | |
| US3749703A (en) | Asn15-bovine thyrocalcitonin | |
| EP0378432B1 (en) | Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation | |
| US4330532A (en) | Angiotensin-II analogues with antagonizing effects, containing an α-hydroxycarboxylic acid residue in position 8, and a process for the preparation thereof | |
| US5118669A (en) | Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators | |
| JPH04282398A (ja) | アンジオテンシン変換酵素阻害ペプチド | |
| JPH0631314B2 (ja) | 新規なゴナドリベリン誘導体 | |
| US4868156A (en) | Pharmaceutical preparation containing a dipeptide with cell growth regulating effect | |
| US5223487A (en) | Peptides as antiallergic agents | |
| WO2008050161A2 (en) | Peptides for activation of angiogenesis, pharmaceutical compounds containing same and use of these compounds | |
| JPH06239885A (ja) | ペプチド誘導体及びその用途 | |
| JPH0717999A (ja) | ペプチド誘導体及びその用途 | |
| HU196226B (en) | Process for producing new tripeptide derivatives of antiamnesic activity and pharmaceutical compositions containing them as active components | |
| JPH0641193A (ja) | ペプチド誘導体およびその用途 |